Carlo Incerti
Director/Board Member at DYNE THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Network origin in Carlo Incerti first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.
218
| Subsidiary | Medical Specialties | 218 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.
39
| Private Company | Investment Managers | 39 |
| Public Company | Biotechnology | 20 | |
| Subsidiary | Pharmaceuticals: Major | 12 | |
Università degli Studi di Modena e Reggio Emilia
11
| College/University | Other Consumer Services | 11 |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
EryDel SpA
 EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy.
9
| Subsidiary | Medical Specialties | 9 |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Carlo Incerti via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Executive Officer Sales & Marketing Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| DYAX CORP. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| SANOFI | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Nyenrode Business Universiteit | College/University | Undergraduate Degree Graduate Degree | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chairman | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor Consultant / Advisor | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Director/Board Member | |
| Bentley University | College/University | Graduate Degree Graduate Degree Masters Business Admin | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Undergraduate Degree Director/Board Member | |
| University of Massachusetts | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal | |
| University College London | College/University | Doctorate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
| University of Groningen | College/University | Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Graduate Degree | |
| University of Bocconi | College/University | Masters Business Admin Undergraduate Degree Graduate Degree | |
| University of Milan | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Director/Board Member | |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Founder Director/Board Member | |
Ossianix, Inc.
 Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Generic | Director/Board Member Founder | |
| UNIQURE N.V. | Biotechnology | Chairman Founder Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| QUINCE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Atlas Venture Life Science Advisors LLC
 Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor | |
| REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member Director/Board Member Director of Finance/CFO | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Chairman Director/Board Member | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director of Finance/CFO Investor Relations Contact Comptroller/Controller/Auditor Corporate Officer/Principal | |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member Director/Board Member | |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Chairman Director/Board Member | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Chairman Director/Board Member | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Founder | |
Oxitope Pharma BV
 Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
| ENGENE HOLDINGS INC. | Biotechnology | Director/Board Member Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Director/Board Member |
Statistics
International
| United States | 26 |
| Netherlands | 11 |
| United Kingdom | 4 |
| Denmark | 4 |
| Switzerland | 4 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 12 |
| Finance | 5 |
| Commercial Services | 3 |
Operational
| Director/Board Member | 511 |
| Corporate Officer/Principal | 192 |
| Independent Dir/Board Member | 104 |
| Chairman | 91 |
| Founder | 71 |
Most connected contacts
| Insiders | |
|---|---|
| Ed Mathers Mathers | 47 |
| Henri A. Termeer | 42 |
| Christopher Viehbacher | 37 |
| Hugo Slootweg | 34 |
| Patrick Volkert Vink | 30 |
| Nanna Liebach Lüneborg | 29 |
| Michael Hayden | 27 |
| Edward Hurwitz | 27 |
| Peter Andersen | 26 |
| Graziano Seghezzi | 26 |
| Laura Iris Ferro | 24 |
| Jason Rhodes | 24 |
| Elizabeth Marie Robinson | 22 |
| Ralph Victor Whitworth | 21 |
| David Lubner | 19 |
- Stock Market
- Insiders
- Carlo Incerti
- Company connections
